Clinical Trials in Rheumatology
Springer London Ltd (Verlag)
978-1-84996-383-1 (ISBN)
- Titel erscheint in neuer Auflage
- Artikel merken
A huge number of therapeutic studies has been published in rheumatology and clinical immunology. This number grows substantially by the year. As such, it becomes increasingly difficult to keep track of this multitude of studies and the ensuing therapeutic trends. Further to this, a particular study can be referred to in a variety of ways, either as a shortened version of the title or an acronym, adding to the confusion. This book "Clinical Trials in Rheumatology" provides a summary of the important studies in the field for easy reference. Every study is shown with name, acronym (if in existence), authors, complete citation, study design, results, and summary. An acronym finder is supplied at the beginning of the book. This book is a valuable reference tool for rheumatologists and other clinical specialties, as well as for research scientists interested in immunomodulatory and selected other drug therapies in rheumatologic diseases.
Rudiger Muller, MD, is Senior Consultant in rheumatology at the Kantonsspital in St Gallen, Switzerland. Johannes von Kempis, MD, is the Head of the Rheumatology Division at Kanstonsspital in St Gallen, Switzerland.
Rheumatoid Arthritis:- Corticosteroids:- Atorvastatin:- Azathioprine:- Chloroquine/Hydroxychloroquine:- Ciclosporin:- Cyclophosphamide:- Gold:- Leflunomide:- Methotrexate:- Sulfasalazine:- Tacrolimus:- Combination Therapy:- Methotrexate and Hydroxychloroquine:- Methotrexate and Doxycycline:- Methotrexate and Sulfasalazine:- Methotrexate and Civlosporin:- Methotrexate and Hydroxychloroquine and Sulfasalazine:- Methotrexate and Leflunomide:- Methotrexate and Azathioprine:- Methotrexate and Gold:- Gold and Hydroxychloroquine:- Abatacept:- Adalimumab:- Anakinra:- Certolizumab pegol:- Etanercept:- Golimumab:- Infliximab:- Rituximab:- Tocilizumab:- Ankylosing Spondylitis:- Corticosteroids:- Cyclophosphamide:- Leflunomide:- Methotrexate:- Pamindronate:- Sulfasalazine:- Combination therapy:- Adalimumab:- Etanercept:- Golimumab:- Infliximab:- Psoriatic Arthritis;- Chloroquine/Hydroxychloroquine:- Ciclosporin:- Leflunomide:- Methotrexate:- Sulfasalazine:- Adalimumab:- Alefacept:- Etanercept:- Golimumab:- Infliximab:- Ustekinumab:- Systemic Lupus erythematosus:- Corticosteroids:- Azathioprine:- Chloroquine/Hydroxychloroquine:- Cyclophosphamide:- Leflunomide:- Methotrexate:- Mycophenolate mofetil:- Raloxifene:- Tacrolimus:- Combination:- Azathioprine + Ciclosporine:- Hydroxychloroquine and Mycophenolate mofetil:- Infliximab:- Rituximab:- Antiphospholipid Syndrome:- Aspirin vs. Heparin:- Heparin vs. Intravenous Immunoglobulins:- Prednisone + Aspirin:- Warfarin:- Progress. System Sclerosis:- Corticosteroids:- Ambrisentan:- Azathioprine:- Bosentan:- Chlorambucil:- Ciclosporin:- Colchicine:- Cyclophosphamide:- D-Penicillamine:- Methotrexate:- Mycophenolate mofetil:- 5-Fluorouracil:- Etanercept:- Infliximab: Rituximab: Plasma exchange:- Stem cell transplantation:- Raynaud,s phenomenon:- Bosentan:- Diltiazem:- Glyceryl Trinitrate:- Iloprost:- Nifedipine:- Sildenafil:- Dermato/Polymyositis:- Corticosteroids:- Cyclophosphamide:- Immunoglobulins:- Methotrexate:- Mycophenolate mofetil:- Anti-TNF:- Etanercept:- Rituximab:- Sjogren's syndrome:- Hydroxychloroquine:- Leflunomide:- Methotrexate:- Mycophenolate mofetil:- Pilocarpine:- Etanercept:- Infliximab:- Rituximab:- Takayasu arteritis:- Methotrexate:- Mycophenolate mofetil:- Anti-TNF:- Giant cell arteritis:- Corticosteroids:- Ciclosporin:- Methotrexate:- Etanercept:- Infliximab:- Polymyalgia rheumatica:- Corticosteroids:- Azathioprine:- Methotrexate:- Etanercept:- Infliximab:- ANCA-associated Vasculitis incl. trials combined with polyarteritis nodosa:- Azathioprine/:- Co-Trimoxazole:- Cyclophosphamide:- Methotrexate:- Mycophenolate mofetil:- Anti-thymocyte globulin:- Etanercept:- Immunoglobulin:- Infliximab:- Plasma exchange:- Purpura Schoenlein Henoch:- Corticosteroids:- Azathioprine:- Ciclosporine:- Cyclophosphamide:- Morbus Behcet:- Corticosteroids:- Azathioprine:- Ciclosporine:- Colchicine:- Cyclophosphamide:- Dapsone:- Methotrexate:- Mycophenolate mofetil:- Tacrolimus:- Thalidomide:- Etanercept:- Infliximab:- Interferon alfa-2a:- Acronyms:- Abbreviations:-
| Zusatzinfo | black & white illustrations |
|---|---|
| Verlagsort | England |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Gewicht | 1249 g |
| Einbandart | gebunden |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Rheumatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Medizin / Pharmazie ► Pharmazie | |
| Studium ► 2. Studienabschnitt (Klinik) ► Pharmakologie / Toxikologie | |
| ISBN-10 | 1-84996-383-5 / 1849963835 |
| ISBN-13 | 978-1-84996-383-1 / 9781849963831 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
